Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

Sonja Althammer, PhD
Published: Wednesday, Nov 16, 2016


Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.  
 
It was already known that PD-L1 by itself serves as biomarker to predict response to durvalumab.  However, researchers hypothesized that both CD8+ and PD-L1+ cells were critical for patient response to immunotherapies.
 
The study determined that the combination of CD8+ and PD-L1+ both correlated with response and improved overall survival with durvalumab. An independent study is planned to validate these results.
 
SELECTED
LANGUAGE

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.  
 
It was already known that PD-L1 by itself serves as biomarker to predict response to durvalumab.  However, researchers hypothesized that both CD8+ and PD-L1+ cells were critical for patient response to immunotherapies.
 
The study determined that the combination of CD8+ and PD-L1+ both correlated with response and improved overall survival with durvalumab. An independent study is planned to validate these results.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer ManagementMar 30, 20191.5
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x